Articles tagged with Solid Tumors
Complimentary press passes are now available for the Association for Molecular Pathology 2026 Annual Meeting & Expo in Seattle, featuring over 200 exhibiting companies, 60 educational sessions, and 500 poster presentations. Reporters can register to attend in person or access press materials online.
UCLA scientists develop a stem cell-based platform to produce uniform T cells that target solid tumors in a unique way, avoiding a common side effect. The therapy, called AlloESO-T cells, keeps tumors in check and extends survival in mouse models of ovarian, melanoma, and prostate cancers.
Researchers developed a new approach called SHIFTERS that uses focused ultrasound to temporarily 'light up' solid tumors, giving cancer-fighting immune cells a target they can recognize. The technology allows doctors to control where and when treatment switches on, potentially making solid tumors easier to treat.
Researchers developed an AI model that analyzes routine whole histopathology images to predict cancer subtype, genetic mutations, and survival outcomes across 32 solid cancers. The model achieved a strong predictive accuracy score for TP53 mutation detection and demonstrated the ability to infer RNA expression levels and tumor taxonomy.
Scientists at Gladstone Institutes and UCSF discovered a pair of genetic edits that make CAR-T cells more effective against solid tumors. The new CRISPR screening platform enables the study of gene edits on CAR-T cells inside living mice, uncovering therapeutic targets previously missed in conventional cell culture systems.
Researchers at USC have developed a genetic tool called the Mechano-Recorder to measure tumor cell softness. This insight can help target hard-to-reach cancer stem-like cells for destruction, potentially improving cancer treatment outcomes.
Insilico Medicine presents first-in-human Phase 1 study data for its novel AI-designed pan-TEAD inhibitor ISM6331, targeting complex oncogenic drivers like the Hippo pathway. The study assesses safety, pharmacokinetics, and preliminary antitumor activity in patients with advanced mesothelioma and other solid tumors.
Researchers at Kobe University have successfully created a subclass of T cells that can be used across patients and reproduceably turned back into those T cells. These cells attack and shrink human patient-derived colorectal cancer tumors implanted in mice, offering potential for future systemic therapy.
Next-generation BET inhibitors targeting BD2, PROTAC degraders, and rational combinations offer renewed hope for treating solid tumors. Clinical trials have shown modest responses, especially in NUT carcinoma and castration-resistant prostate cancer.
A new study published in Science Advances identifies IRS4 as a promising drug target for multiple solid tumors, offering hope for safer cancer treatments. By using AI and natural mutations, researchers prioritized targets with high therapeutic indexes to minimize toxicity.
Research from Lund University reveals that stiffer tumor tissue triggers a chain of molecular events driving cancer cells to invade surrounding tissue. The studies identified key proteins and pathways involved in this process, offering new insights into the mechanical properties of tumor microenvironments.
The Phase I MYTHIC trial demonstrated a strong synergy between zedoresertib and lunresertib, showing durable regressions and consistent tumor shrinkage in patients with ovarian cancer. The combination achieved an overall disease control rate of 68.5% and a molecular response rate of 47%.
Researchers from UT MD Anderson Cancer Center present studies on single-cell technologies, integrative computational approaches, and experimental therapeutics, highlighting innovations in mRNA vaccines and spatial multi-omics techniques. The studies aim to improve immunotherapy responses and detect treatment-resistant glioma cells.
The study found that immune checkpoint inhibitors significantly improved key clinical outcomes, including disease-free survival and distant metastasis-free survival. However, no clear improvement in overall survival was observed across studies, highlighting the need for careful patient selection and monitoring.
Researchers have developed a new CAR T therapy that targets tumor-supporting cells in pancreatic cancer, paving the way for a potentially safer and more effective treatment. The therapy uses lipid nanoparticles to deliver CAR instructions directly to patient T cells, resulting in higher expression rates and improved efficacy compared t...
Blocking two key 'don't eat me signals' in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in glioblastoma models. Researchers found that simultaneously blocking CD47 and CD24 improved immunotherapy response, allowing macrophages to better recognize and attack cancer cells.
Insilico Medicine received a USD 5 million milestone payment from Menarini Group after completing first-in-human dosing in a Phase 1 study of MEN2501, a small molecule inhibitor targeting cancers with chromosome instability. This achievement follows the completion of a successful Phase 1 clinical trial.
PRMT5 promotes proliferation, metastasis, therapy resistance, and an immunosuppressive tumor microenvironment in various solid malignancies. Targeting PRMT5 with inhibitors has shown promising therapeutic effects in several cancers.
The VT3989 trial demonstrated a disease control rate of 86% in refractory mesothelioma patients, with notable partial responses and stable disease. The YAP-TEAD inhibitor also showed an encouraging safety profile, supporting continued clinical development in this unmet clinical need.
Researchers analyzed data from over 10,000 solid tumor samples and found that more than 90 percent contained genetic changes that could guide treatment. The study identified biomarkers associated with approved therapies and rare mutations missed by simpler tests.
Researchers propose a synergistic combination strategy using systemic type I interferons (IFN-I) and local TLR7/8 agonists to enhance dendritic cell activation and inhibit metastatic tumors. This approach enhances early innate immune control and later induces CD8+ T cell responses.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
The EVOaware project aims to develop an innovative platform that addresses tumour resistance to therapies by using advanced tissue imaging technologies and integrating genetic screening, lineage tracing, and spatial omics techniques. This platform has the potential to accelerate the discovery and development of new cancer therapies.
A new review identifies CHEK2 as a potential biomarker for predicting response to immunotherapy and suggests that combining CHEK2 inhibitors with existing therapies may enhance anti-tumor effects. This could lead to improved treatment outcomes in solid tumors.
Insilico Medicine has completed the first-in-patient dosing of ISM3412, a novel MAT2A inhibitor with potential as a best-in-class treatment for locally advanced and metastatic solid tumors. The Phase 1 study aims to evaluate safety, tolerability, and preliminary anti-tumor efficacy of ISM3412.
A systematic review and meta-analysis found elevated circPVT1 expression associated with poorer overall survival in patients with solid tumors. The study also revealed correlations between circPVT1 levels and larger tumor size, lymph node metastasis, distant metastasis, and advanced tumor-stage.
AIC100 demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, including anaplastic thyroid cancer (ATC) and relapsed/refractory poorly differentiated thyroid cancer (PTDC). The therapy showed significant tumor shrinkage and disease control in 56% of patients.
A Phase II trial found durable antitumor activity in patients with BRCA1/2 mutations treated with olaparib and pembrolizumab, with 8.3% complete response rate
The treatment demonstrated early signals of efficacy, with 65.7% of patients experiencing lasting stable disease, and was generally well-tolerated, with most adverse events being mild and manageable.
A phase 1 trial involving 40 patients showed significant responses to the new cell therapy IMA203, with half of non-responders achieving lasting response. The therapy targets PRAME peptide produced by many tumors and was well-tolerated.
Preet Chaudhary and Michael Selsted, USC innovators, recognized by the National Academy of Inventors for their work on harnessing the power of the immune system. Their research aims to develop new treatments for diseases such as cancer, rheumatoid arthritis, and sepsis.
Dr. Nowicki's team has engineered 'supercharged' T cells that produce extra TNF-alpha to boost cancer-fighting ability, offering a potentially more precise and toxic-free treatment option. The new funding will help test these enhanced T cells in preclinical models to evaluate their effectiveness.
The ESMO Sarcoma and Rare Cancers Congress 2025 will bring together experts to present and discuss developments in diagnosing and treating rare solid tumours. The event will focus on immunotherapy, global challenges, and opportunities for international collaboration.
Researchers discovered that by targeting the Elovl1 enzyme, T cells can harness fatty acid oxidation for energy, increasing their survival and effectiveness against cancer. This metabolic reprogramming approach enhances antitumor activity and improves treatment outcomes in experimental models of melanoma and pancreatic cancer.
The ESMO Targeted Anticancer Therapies Congress 2025 features state-of-the-art presentations on new targets, tumour-agnostic drug development, and the role of artificial intelligence in cancer treatment. The congress also highlights recent study results and their potential impact on precision medicine.
A new approach to cancer therapy is being developed by inhibiting mechanotransduction, a process that regulates processes such as tumour progression and wound healing. The INTROPY project aims to validate the potential of six molecules in blocking this process, offering a new strategy for cancer treatment.
Insilico Medicine has successfully dosed the first patient in its global Phase I clinical trial of ISM6331, a potent pan-TEAD inhibitor. The treatment demonstrates superior efficacy and safety in preclinical studies, with potential synergistic anti-tumor effects and overcoming drug resistance.
A new study published in Cell reveals significant differences in the immune response of children and adults to cancer, with potential implications for targeted therapies. The research shows that children's tumours are generally less inflammatory and have fewer mutations, making them appear less foreign to their immune system.
Researchers at Johns Hopkins Medicine identified a new epigenetic approach to target colorectal cancer, using a mouse protein that disrupts cancer-causing chemical changes in genes. The study found that the protein, STELLA, can be used to develop a drug strategy to treat solid tumors.
Insilico Medicine has received its first clinical milestone payment of $10 million from Exelixis for XL309, a selective USP1 inhibitor discovered with the company's AI platform. The drug is being developed for advanced solid tumors and has shown efficacy in preclinical studies.
Researchers at Penn State College of Medicine have re-engineered natural killer immune cells with blue light-activated protein function, allowing them to infiltrate and kill solid tumor spheroids. The technology has shown promising results in killing breast cancer and melanoma cells within seven days.
Children who survived childhood brain cancer are more likely to struggle academically, with a greater chance of being held back and performing poorly on state testing. The study's findings highlight the need for better support and resources to help these students succeed.
Researchers have discovered a novel immunotherapy approach using natural killer T cells to combat solid tumors. By targeting tumor-associated macrophages and promoting systemic immune responses, CAR-natural killer T cells demonstrate superior antitumor activity compared to traditional CAR-T therapy.
Researchers have identified a 'forcefield-like' defense system in solid tumors, which uses small extracellular vesicles to block nanoparticle-based therapies. The study found that tumor cells release sEVs carrying proteins that block the activity of cytotoxic T cells and intercept nanoparticles like a decoy.
Researchers have designed molecular 'cages' that selectively target and eliminate cancer cells in acidic microenvironments. The study, led by CSIC, proposes a new approach to overcome chemotherapy limitations, with potential for future ionophore development.
Researchers found saruparib to be superior and durable in treating PDX models with BRCA1/2 alterations, outperforming olaparib in terms of complete response rate and progression-free survival. The study's results suggest the promise of PARP1 selective inhibitors as a new therapeutic option for patients with advanced solid tumors.
The study compared FDG-PET/CT and CT for evaluating treatment response in unresectable malignant pleural mesothelioma patients. The results showed that both imaging modalities provided accurate findings for tumor response evaluation, with high concordance between the two methods.
Researchers created nanomicelles containing substances already approved for human use, which reduced inflammation in the tumor microenvironment and facilitated the action of the immune system. The treatment induced a reduction of over five times in tumor volume compared to untreated tumors.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
Researchers have developed a breakthrough therapy that can adapt CAR-T cell therapy to target solid tumors, potentially transforming cancer treatment. The therapy uses a novel antibody and costimulatory protein to activate T cells, overcoming the challenges of immune suppression in solid tumors.
The ECOG-ACRIN Cancer Research Group has launched the ComboMATCH-E5 trial, evaluating the combination of sotorasib and panitumumab in patients with KRAS G12C-mutated advanced solid tumors. The study aims to assess the efficacy and safety of the combination in this patient population.
A late University of Virginia School of Medicine scientist's research on the SAS1B protein could lead to new cancer treatments for multiple cancers. The discovery has the potential to selectively target cancer cells while sparing healthy tissue.
Researchers unveil innovative strategies to overcome metabolic constraints in CAR-T cell therapy, aiming to boost its efficacy in treating solid tumors. Metabolic interventions targeting immunosuppressive metabolites, metabolite uptake, and mitochondrial metabolism are proposed to enhance anti-tumor activity.
Researchers found that individuals with a single mutated copy of the MUTYH gene have a modest increase in susceptibility to a subset of solid tumors, including adrenal gland cancers and pancreatic islet cell tumors. This suggests that MUTYH variants may be involved in a broader range of cancers than previously known.
NeXT Personal assay detects up to ~1,800 somatic variants specific to the patient's tumor with a detection threshold of 1.67 PPM and 99.9% specificity. The assay showed linearity over a range of 0.8 to 300,000 PPM.
A study by UNC researchers found that a metabolic enzyme called Acetyl-CoA Carboxylase (ACC) causes T cells to store fat rather than burning it for energy in solid tumors. Inhibiting ACC expression allowed T cells to persist better in tumors, leading to potential breakthroughs in immunotherapies like CAR T-cell therapies.
Early trial results from six patients with recurrent glioblastoma show reduced tumor sizes after administering dual-target CAR T cells targeting EGFR and IL13Rα2 intrathecally. This 'dual-target' approach may outsmart the defense systems of GBM, leading to more effective therapies.
Researchers discovered GZ17-6.02's ability to interact with proteasome inhibitors in a greater than additive fashion to kill multiple myeloma cells and alone inhibit inhibitor-resistant cells. The compound combination also activated key pathways and increased autophagosome formation, leading to tumor cell killing.
Researchers found GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells, activating key pathways including ATM, AMPK, NFκB, and macroautophagy. The compound's unique multi-factorial mechanism suggests potential for treating mycosis fungoides.
Researchers identified NTRK gene fusion in 1.5% of Finnish papillary thyroid cancer patients, with notable co-occurring genetic alterations and favorable treatment outcomes. The study highlights the potential for biobank samples linked to electronic health records to describe patient characteristics and outcomes.